First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107/CAF ®10b

Condition:   Healthy Interventions:   Biological: H107e;   Biological: CAF®10b;   Biological: H107e/CAF®10b - low adjuvant dose;   Biological: H107e/CAF®10b - full adjuvant dose;   Biological: Low dose intranasal H107e;   Biological: Full dose intranasal H107e;   Biological: H107e/CAF®10b;   Biologica l: i.m. placebo;   Biological: BCG;   Biological: i.d. placebo;   Biological: Intranasal H107e Sponsors:   Statens Serum Institut;   Aurum Institute;   Bill and Melinda Gates Foundation;   Leiden University Medical Center;   South African Tuberculosis Vaccine Initiative Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials